PL2007356T3 - Preparaty lipopleksowe przeznaczone do swoistego dostarczania do tkanek naczyniowych śródbłonka - Google Patents
Preparaty lipopleksowe przeznaczone do swoistego dostarczania do tkanek naczyniowych śródbłonkaInfo
- Publication number
- PL2007356T3 PL2007356T3 PL07724432T PL07724432T PL2007356T3 PL 2007356 T3 PL2007356 T3 PL 2007356T3 PL 07724432 T PL07724432 T PL 07724432T PL 07724432 T PL07724432 T PL 07724432T PL 2007356 T3 PL2007356 T3 PL 2007356T3
- Authority
- PL
- Poland
- Prior art keywords
- vascular endothelium
- specific delivery
- lipoplex formulations
- lipoplex
- formulations
- Prior art date
Links
- 210000003989 endothelium vascular Anatomy 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000002479 lipoplex Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06008209 | 2006-04-20 | ||
| PCT/EP2007/003496 WO2007121947A1 (en) | 2006-04-20 | 2007-04-20 | Lipoplex formulations for specific delivery to vascular endothelium |
| EP07724432.5A EP2007356B1 (en) | 2006-04-20 | 2007-04-20 | Lipoplex formulations for specific delivery to vascular endothelium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2007356T3 true PL2007356T3 (pl) | 2016-02-29 |
Family
ID=38481639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07724432T PL2007356T3 (pl) | 2006-04-20 | 2007-04-20 | Preparaty lipopleksowe przeznaczone do swoistego dostarczania do tkanek naczyniowych śródbłonka |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20090074852A1 (pl) |
| EP (2) | EP2007356B1 (pl) |
| JP (4) | JP2009534342A (pl) |
| AU (1) | AU2007241370A1 (pl) |
| CA (1) | CA2649630C (pl) |
| DK (1) | DK2007356T3 (pl) |
| ES (1) | ES2549728T3 (pl) |
| PL (1) | PL2007356T3 (pl) |
| WO (1) | WO2007121947A1 (pl) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005237764B2 (en) | 2004-05-05 | 2011-11-24 | Silence Therapeutics Gmbh | Lipids, lipid complexes and use thereof |
| EP2992902A1 (en) | 2004-12-27 | 2016-03-09 | Silence Therapeutics GmbH | Lipid complexes coated with peg and their uses |
| CA2633065C (en) * | 2005-12-15 | 2016-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Cationic oligonucleotides, automated methods for preparing same and their uses |
| AR067997A1 (es) * | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
| FR2926818B1 (fr) * | 2008-01-30 | 2012-04-06 | Centre Nat Rech Scient | siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE |
| EP2323695B1 (en) | 2008-08-19 | 2018-12-05 | Nektar Therapeutics | Complexes of small-interfering nucleic acids |
| WO2010094491A1 (en) | 2009-02-18 | 2010-08-26 | Silence Therapeutics Ag | Means for inhibiting the expression of ang2 |
| WO2010113172A1 (en) * | 2009-03-31 | 2010-10-07 | Council Of Scientific & Industrial Research | Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference |
| GB0910723D0 (en) | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
| US9937128B2 (en) | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
| US8916693B2 (en) | 2009-09-17 | 2014-12-23 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
| US8359883B2 (en) * | 2009-11-13 | 2013-01-29 | Hasmukh Dholakiya | Gemstone setting |
| WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
| US8349308B2 (en) | 2010-03-26 | 2013-01-08 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| EP2384743A1 (en) * | 2010-04-27 | 2011-11-09 | Zoser B. Salama | Siosomal formulation for intracellular delivery and targeting of therapeutic agents |
| EP2386647A1 (de) * | 2010-05-10 | 2011-11-16 | Qiagen GmbH | Verfahren zur Transfektion einer eurkaryotischen Zelle |
| CN103153283B (zh) * | 2010-06-19 | 2017-05-17 | 健康科学西部大学 | Peg化脂质体包封的糖肽抗生素的新制剂 |
| WO2012005572A1 (en) | 2010-07-06 | 2012-01-12 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| US20120301537A1 (en) * | 2011-05-23 | 2012-11-29 | Delta-Fly Pharma, Inc. | LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF |
| US8592572B2 (en) * | 2011-05-23 | 2013-11-26 | Delta-Fly Pharma, Inc. | Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof |
| SG10201605500TA (en) | 2011-07-06 | 2016-08-30 | Novartis Ag | Cationic oil-in-water emulsions |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| ES2886147T3 (es) | 2011-12-22 | 2021-12-16 | Interna Tech B V | MiARN para el tratamiento del cáncer de cabeza y de cuello |
| WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
| WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
| US10603385B2 (en) | 2013-06-04 | 2020-03-31 | Tribiotica Llc | Methods and compositions for templated assembly of nucleic acid specific heterocompounds |
| CA2932626A1 (en) * | 2013-12-05 | 2015-06-11 | Silence Therapeutics Gmbh | Means for lung specific delivery |
| MX2016008352A (es) * | 2013-12-23 | 2017-01-12 | Dermopartners S L | Procedimiento de preparacion de liposomas de retinaldehido u otros precursores del acido retinoico y producto asi obtenido. |
| WO2016083623A1 (en) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for the treatment of pre-eclampsia |
| CA2968552A1 (en) * | 2014-12-02 | 2016-06-09 | Tribiotica Llc | Methods and kits for theranostic applications |
| CN110114461A (zh) | 2016-08-17 | 2019-08-09 | 博德研究所 | 新型crispr酶和系统 |
| US20200283743A1 (en) | 2016-08-17 | 2020-09-10 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| EP3541940A4 (en) | 2016-11-21 | 2020-10-14 | Tribiotica Llc | PROCEDURE FOR DIRECTED FOLDING ASSEMBLY OR DIMERIZATION OF PROTEINS BY TEMPLATE REACTIONS |
| US11186839B2 (en) | 2016-11-21 | 2021-11-30 | Tribiotica Llc | Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations |
| CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
| JP2020535802A (ja) | 2017-09-21 | 2020-12-10 | ザ・ブロード・インスティテュート・インコーポレイテッド | 標的化核酸編集のための系、方法、及び組成物 |
| EP3704250A1 (en) | 2017-11-03 | 2020-09-09 | InteRNA Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH |
| US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
| KR20210056329A (ko) | 2018-08-07 | 2021-05-18 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규 cas12b 효소 및 시스템 |
| US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
| WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
| US11896713B2 (en) * | 2020-10-22 | 2024-02-13 | Rutgers, The State University Of New Jersey | Strategies to enhance lung cancer treatment |
| WO2022119883A2 (en) * | 2020-12-02 | 2022-06-09 | Merck Sharp & Dohme Corp. | Lipid nanoparticle compositions containing monoester cationic lipids |
| WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2110444T3 (es) | 1990-06-11 | 1998-02-16 | Nexstar Pharmaceuticals Inc | Ligandos de acidos nucleicos. |
| GB2270920B (en) * | 1992-09-25 | 1997-04-02 | Univ Keele | Alginate-bioactive agent conjugates |
| ES2231819T3 (es) * | 1995-06-07 | 2005-05-16 | Inex Pharmaceuticals Corp | Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes. |
| JP2001504448A (ja) | 1996-08-30 | 2001-04-03 | フュルステ，イェンス，ペーター | 核酸の鏡面対称選択および進化 |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6358523B1 (en) * | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
| CO4750643A1 (es) * | 1997-06-13 | 1999-03-31 | Lilly Co Eli | Formulacion estable de la insulina que contiene l-arginina y protamina |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| AU8525098A (en) * | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| CA2403962C (en) * | 2000-03-31 | 2009-12-15 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability |
| AU5454801A (en) * | 2000-04-20 | 2001-11-07 | Univ British Columbia | Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers |
| AU2005237764B2 (en) * | 2004-05-05 | 2011-11-24 | Silence Therapeutics Gmbh | Lipids, lipid complexes and use thereof |
| EP2992902A1 (en) * | 2004-12-27 | 2016-03-09 | Silence Therapeutics GmbH | Lipid complexes coated with peg and their uses |
-
2007
- 2007-04-20 JP JP2009505789A patent/JP2009534342A/ja active Pending
- 2007-04-20 EP EP07724432.5A patent/EP2007356B1/en active Active
- 2007-04-20 PL PL07724432T patent/PL2007356T3/pl unknown
- 2007-04-20 ES ES07724432.5T patent/ES2549728T3/es active Active
- 2007-04-20 EP EP15161527.5A patent/EP2992875A1/en not_active Withdrawn
- 2007-04-20 WO PCT/EP2007/003496 patent/WO2007121947A1/en active Application Filing
- 2007-04-20 US US12/297,611 patent/US20090074852A1/en not_active Abandoned
- 2007-04-20 AU AU2007241370A patent/AU2007241370A1/en not_active Abandoned
- 2007-04-20 CA CA2649630A patent/CA2649630C/en not_active Expired - Fee Related
- 2007-04-20 DK DK07724432.5T patent/DK2007356T3/en active
-
2013
- 2013-11-15 JP JP2013236912A patent/JP2014055167A/ja active Pending
-
2015
- 2015-12-28 JP JP2015256323A patent/JP2016121153A/ja active Pending
-
2016
- 2016-11-01 JP JP2016214343A patent/JP2017048223A/ja active Pending
-
2017
- 2017-03-30 US US15/474,571 patent/US20170296469A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2007356T3 (en) | 2015-10-19 |
| EP2007356A1 (en) | 2008-12-31 |
| CA2649630A1 (en) | 2007-11-01 |
| WO2007121947A1 (en) | 2007-11-01 |
| EP2007356B1 (en) | 2015-08-12 |
| JP2014055167A (ja) | 2014-03-27 |
| CA2649630C (en) | 2016-04-05 |
| US20090074852A1 (en) | 2009-03-19 |
| JP2009534342A (ja) | 2009-09-24 |
| EP2992875A1 (en) | 2016-03-09 |
| US20170296469A1 (en) | 2017-10-19 |
| AU2007241370A1 (en) | 2007-11-01 |
| JP2017048223A (ja) | 2017-03-09 |
| ES2549728T3 (es) | 2015-11-02 |
| JP2016121153A (ja) | 2016-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2007356T3 (pl) | Preparaty lipopleksowe przeznaczone do swoistego dostarczania do tkanek naczyniowych śródbłonka | |
| IL207569A0 (en) | Compositions and methods for drug delivery | |
| EP1942981A4 (en) | DISTRIBUTION OF MEDIUM TO TISSUE | |
| HK1164059A1 (en) | Compositions for drug administration | |
| ZA200900030B (en) | Improvements relating to pharmaceutical compositions | |
| HRP20130109T1 (en) | Caspofungin formulations | |
| EP2001498A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL194176A0 (en) | Pharmaceutical compositions | |
| GB0713625D0 (en) | Pharmaceutical compositions | |
| ZA200710734B (en) | Compositions for drug delivery | |
| EP2056918A4 (en) | CATHETER FOR CELL RELEASE | |
| HK1138732A1 (en) | Pharmaceutical compositions | |
| EP2114145A4 (en) | MEANS FOR PROMOTING PHENYL ALKYL CYCLOXYLIC ACID | |
| HK1180949A1 (en) | Long lasting drug formulations | |
| EP2010162A4 (en) | COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT | |
| IL195764A0 (en) | Compositions and methods for drug delivery | |
| EP2121105A4 (en) | FAST EXCHANGE CATHETER IMPROVED | |
| PL394605A1 (pl) | Trwała złożona kompozycja farmaceutyczna | |
| IL198160A0 (en) | Pharmaceutical formulations | |
| HK1182939A1 (en) | Stable pharmaceutical composition | |
| GB0615461D0 (en) | Pharmaceutical formulations | |
| GB0813031D0 (en) | Pharmaceutical formulations | |
| GB0810217D0 (en) | Pharmaceutical formulations | |
| GB0613428D0 (en) | In situ delivery of probotic formulations | |
| GB0622964D0 (en) | Pharmaceutical compositions |